Best treatment strategies for weight loss after stopping GLP-1 drugs
A Cleveland Clinic analysis of more than 20,000 patients, has found that bariatric surgery produced greatest weight loss at two years, followed by switching between GLP-1 medications and switching to a non-GLP1 medication. The findings were presented by the lead author of the study, Dr Hamlet Gasoyan, a researcher with Cleveland Clinic’s Center for Value-Based Care Research, at ObesityWeek 2026, the Obesity Society’s annual meeting in National Harbor, MD.
“The encouraging news is that, for patients who need to stop their injectable GLP-1 medication, it does not mean that their obesity treatment journey has to end,” said Gasoyan. “Our findings could support patient-clinician discussions about alternative therapy options for patients who consider switching or stopping injectable semaglutide or tirzepatide.”
The study found that patients who initially took injectable GLP-1 drugs, such as semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbouund), achieved the greatest weight loss over two years if they later had bariatric surgery. Patients who switched between semaglutide and tirzepatide, stayed on their original medication or moved to another obesity treatment also experienced significant weight loss over the two-year follow-up. Those who discontinued the medication with no further treatment had the smallest weight loss and the least improvement in blood sugar control and blood pressure.
The percentage of US adults using GLP-1 medications for weight loss increased to 11% in 2026 from 3% in 2024, according to the 2026 Gallup National Health and Well-Being Index. Overall, 15% said they had used the drugs. Cost, insurance limitations, and side effects remain common reasons patients stop treatment.
The study analysed electronic health records from 20,486 Cleveland Clinic patients who used semaglutide or tirzepatide for at least three months between 2021 and 2023. Gasoyan and colleagues compared outcomes across five treatment strategies: remaining on the initial GLP-1 medication, switching between semaglutide and tirzepatide, transitioning to another obesity medication, undergoing bariatric surgery, or discontinuing obesity treatment without additional pharmacological or surgical treatment.
Among the five strategies, bariatric surgery produced the largest average weight loss, with patients losing an average of 28% of their body weight at two years.
“When a patient stops a GLP-1 medication, the most important question is what comes next,” said co-author, Dr Ali Aminian, director of Cleveland Clinic's Bariatric and Metabolic Institute. “In our study, patients who stopped all treatment had the least weight loss and the smallest metabolic benefits, while those who moved on to another effective therapy, particularly bariatric surgery, did considerably better.”
Switching between semaglutide and tirzepatide was associated with greater weight loss, with patients experiencing an average of 16% of weight loss at two years, compared with nearly 11% among those who stayed on the medication they were initially prescribed. Patients who switched from semaglutide to tirzepatide lost more weight than those who stayed on semaglutide. However, among patients who started on tirzepatide, remaining on the original medication was associated with greater weight loss than switching to semaglutide.
Researchers found that transitioning to another obesity medication was associated with an average 8% reduction in body weight at two years. Medications used in that group included liraglutide (Saxenda), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), orlistat (Xenical, Alli), phentermine (Adipex-P, Lomaira), topiramate (Topamax), bupropion (Wellbutrin), pramlintide (Symlin), zonisamide (Zonegran) and dulaglutide (Trulicity).
The benefits were not limited to weight loss. Among patients with Type 2 diabetes, bariatric surgery led to the greatest improvements in A1C levels at one year, followed by switching between semaglutide and tirzepatide, remaining on the original medication, and switching to another obesity medication. Patients with hypertension also saw greater reductions in blood pressure when they continued treatment than when they stopped.
By comparison, those who stopped treatment without further weight-management care had the smallest average weight loss, 4%, and experienced minimal improvements in blood sugar control and blood pressure.
“Obesity is a complex, chronic disease, and we cannot approach treatment with a one-size-fits-all approach,” added Gasoyan. “We will continue our research in this field to help patients choose treatments based on their individualized expected benefits and risks, aligned with their preferences.”
The findings were featured in the paper, 'Comparative effectiveness of obesity treatments after initial therapy with semaglutide or tirzepatide: a target trial emulation using data from Cleveland Clinic electronic health records', published in eClinicalMedicine. To access this paper, please click here




Comments